Aptose Biosciences Beheer

Beheer criteriumcontroles 3/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

William Rice

Algemeen directeur

US$924.7k

Totale compensatie

Percentage CEO-salaris	67.4%
Dienstverband CEO	11yrs
Eigendom CEO	0.2%
Management gemiddelde ambtstermijn	3.5yrs
Gemiddelde ambtstermijn bestuur	11yrs

Recente managementupdates

Recent updates

Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth

Sep 30

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Feb 07

Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?

Jan 03

We're Not Very Worried About Aptose Biosciences' (TSE:APS) Cash Burn Rate

Nov 29

Jotin Marango Is The Senior VP & Chief Business Officer of Aptose Biosciences Inc. (TSE:APS) And They Just Sold 26% Of Their Shares

Jul 11

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Jun 27

Analyse CEO-vergoeding

Hoe is William Rice's beloning veranderd ten opzichte van Aptose Biosciences's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Jun 30 2024	n/a	n/a	-US$40m
Mar 31 2024	n/a	n/a	-US$47m
Dec 31 2023	US$925k	US$623k	-US$51m
Sep 30 2023	n/a	n/a	-US$49m
Jun 30 2023	n/a	n/a	-US$48m
Mar 31 2023	n/a	n/a	-US$44m
Dec 31 2022	US$2m	US$599k	-US$42m
Sep 30 2022	n/a	n/a	-US$56m
Jun 30 2022	n/a	n/a	-US$58m
Mar 31 2022	n/a	n/a	-US$61m
Dec 31 2021	US$2m	US$582k	-US$65m
Sep 30 2021	n/a	n/a	-US$56m
Jun 30 2021	n/a	n/a	-US$58m
Mar 31 2021	n/a	n/a	-US$60m
Dec 31 2020	US$12m	US$582k	-US$55m
Sep 30 2020	n/a	n/a	-US$48m
Jun 30 2020	n/a	n/a	-US$42m
Mar 31 2020	n/a	n/a	-US$32m
Dec 31 2019	US$2m	US$562k	-US$26m
Sep 30 2019	n/a	n/a	-US$25m
Jun 30 2019	n/a	n/a	-US$24m
Mar 31 2019	n/a	n/a	-US$28m
Dec 31 2018	US$2m	US$540k	-US$29m
Sep 30 2018	n/a	n/a	-US$26m
Jun 30 2018	n/a	n/a	-US$23m
Mar 31 2018	n/a	n/a	-US$15m
Dec 31 2017	US$983k	US$520k	-US$12m

Compensatie versus markt: De totale vergoeding ($USD 924.67K ) William } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de Canadian markt ($USD 172.65K ).

Compensatie versus inkomsten: De vergoeding van William is het afgelopen jaar in lijn geweest met de bedrijfsprestaties.

CEO

William Rice (65 yo)

11yrs

Tenure

US$924,668

Compensatie

Dr. William G. Rice, Ph D., had served as an Independent Director of Oncolytics Biotech Inc. since June 08, 2015 until June 30, 2021. He has been the Chief Executive Officer and President of Aptose Bioscie...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
William Rice	Chairman	11yrs	US$924.67k	0.19% CA$ 18.5k
Fletcher Payne	Senior VP	2.3yrs	US$611.37k	0.040% CA$ 4.0k
Rafael Bejar	Senior VP & Chief Medical Officer	4.8yrs	US$750.08k	0.040% CA$ 4.0k
Marc Wiles	Senior Vice President of Regulatory Affairs	1.3yrs	geen gegevens	geen gegevens

3.5yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van APS wordt beschouwd als ervaren (gemiddelde ambtstermijn 3.5 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
William Rice	Chairman	11yrs	US$924.67k	0.19% CA$ 18.5k
Mark Vincent	Independent Director	17.1yrs	US$127.68k	0.0024% CA$ 233.9
Bernd Seizinger	Independent Director	2.1yrs	US$132.17k	0.094% CA$ 9.2k
Denis Burger	Lead Independent Director	17.1yrs	US$172.17k	0.0080% CA$ 780.1
Stephen Howell	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Daniel Von Hoff	Member of Scientific Advisory Board	no data	geen gegevens	geen gegevens
Erich Platzer	Independent Director	9.8yrs	US$123.67k	0.19% CA$ 18.2k
Warren Whitehead	Independent Director	13.5yrs	US$122.68k	0.0055% CA$ 540.3
Brian Druker	Chairman of Scientific Advisory Board	11yrs	geen gegevens	geen gegevens
Michael Andreeff	Member of Scientific Advisory Board	9.6yrs	geen gegevens	geen gegevens
Carol Ashe	Independent Director	6.2yrs	US$123.67k	0% CA$ 0

11.0yrs

Gemiddelde duur

71.5yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van APS zijn ervaren en ervaren (gemiddelde ambtstermijn van 11 jaar).

Aptose Biosciences Beheer

Beheer criteriumcontroles 3/4

Belangrijke informatie

Recente managementupdates

Aptose Biosciences Inc., Annual General Meeting, May 28, 2024

Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer

Independent Director recently bought CA$72k worth of stock

Insufficient new directors

Aptose Biosciences Inc. Appoints Bernd R. Seizinger to the Board of Directors

Aptose Appoints Fletcher Payne as Chief Financial Officer

Recent updates

Aptose Biosciences Receives Staff Determination Letter from Nasdaq Due to Failure to Meet the Terms of an Extension

New minor risk - Share price stability

New major risk - Negative shareholders equity

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $10 million.

Aptose Announces Receipt of Deficiency Notice from Nasdaq

Aptose Biosciences Inc. has completed a Follow-on Equity Offering.

New major risk - Revenue and earnings growth

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $4.43325 million.

New major risk - Financial position

Aptose Biosciences Inc. to Report Q1, 2024 Results on May 14, 2024

Aptose Biosciences Receives a Letter from the Nasdaq Stock Market Stating the Company Was Not in Compliance with Nasdaq Listing Rule 5550(b)(1)

New major risk - Negative shareholders equity

Aptose Biosciences Inc., Annual General Meeting, May 28, 2024

Aptose Biosciences Inc. to Report Q4, 2023 Results on Mar 26, 2024

Aptose Biosciences Receives Deficiency Letter from The Nasdaq Stock Market LLC

Aptose Biosciences Inc. announced that it has received $4 million in funding from Hanmi Pharm. Co., Ltd.

New major risk - Shareholder dilution

Aptose Biosciences Inc. has completed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Biosciences Inc. has filed a Follow-on Equity Offering in the amount of $16.799998 million.

Aptose Tuspetinib Clinical Data Featured in Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Appoints Fletcher Payne as Chief Business Officer

New major risk - Financial position

Aptose Tuspetinib Clinical Data Selected for Oral Presentation at the 2023 ASH Annual Meeting

Aptose Biosciences Inc. Presents Highlights from Clinical Update Webcast Featuring Latest Available Data on AML Drug Tuspetinib

New major risk - Share price stability

Aptose Biosciences Inc. to Report Q3, 2023 Results on Nov 09, 2023

Aptose to Hold Clinical Update and KOL Data Review of AML Drug Tuspetinib on Monday, October 30th

Independent Director recently bought CA$72k worth of stock

Aptose Biosciences Inc. Provides A Recent Update from an Ongoing Aptivate Phase 1/2 Clinical Trial with the Company's Lead Agent, Tuspetinib

Aptose Biosciences Inc. announced that it expects to receive CAD 7 million in funding from Hanmi Science Co., Ltd.

New minor risk - Share price stability

Aptose Biosciences Inc. to Report Q2, 2023 Results on Aug 10, 2023

Aptose Biosciences Meets Nasdaq Minimum Bid Price Compliance

Aptose Biosciences Inc. Presents Highlights from Clinical Update

Aptose Biosciences Inc. announced that it expects to receive CAD 25 million in funding

Forecast to breakeven in 2025

Here's Why We're Watching Aptose Biosciences' (TSE:APS) Cash Burn Situation

Aptose Biosciences Inc. Updates Clinical Responses, Breadth of Activity, and Safety Across Four Dose Levels of Tuspetinib in Difficult-to-Treat Acute Myeloid Leukemia Populations

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Aptose Biosciences Inc. Treats First Patient with Continuous Dosing of New “G3” Formulation of Luxeptinib

Insufficient new directors

Aptose Biosciences Inc. to Report Q3, 2022 Results on Nov 01, 2022

Aptose Biosciences Inc. Appoints Bernd R. Seizinger to the Board of Directors

Aptose Biosciences Inc.’s New G3 Formulation of Luxeptinib Boosts Bioavailability

We're Keeping An Eye On Aptose Biosciences' (TSE:APS) Cash Burn Rate

Aptose Biosciences Receives a Deficiency Letter from the Nasdaq Listing Qualifications Department Regarding Minimum Bid Price Requirement

Aptose Biosciences Inc. to Report Q2, 2022 Results on Aug 02, 2022

Aptose Appoints Fletcher Payne as Chief Financial Officer

Aptose Receives Fast Track Designation for Hm43239 in Relapsed/Refractory Aml Patients and Flt3 Mutation

Insufficient new directors

Aptose Biosciences Inc. to Report Q1, 2022 Results on May 09, 2022

Aptose Biosciences Inc. Announces Resignation of Dr. Jotin Marango as Chief Financial Officer

We Think Aptose Biosciences (TSE:APS) Needs To Drive Business Growth Carefully

Aptose Biosciences Inc. Provides Update on APTO-253 Program

Independent Director recently bought CA$408k worth of stock

Aptose Biosciences Inc. Announces HM43239 Demonstrates Durable Clinical Benefit in Acute Myeloid Leukemia

Companies Like Aptose Biosciences (TSE:APS) Are In A Position To Invest In Growth

Insufficient new directors

Independent Director recently sold CA$83k worth of stock

Aptose Presents Highlights from EHA2021 Virtual Congress During Corporate Update Event

Consensus forecasts updated

Executive VP, Corporate Secretary, CFO & COO has left the company

Consensus revenue estimates increase to US$928.6k

Aptose Biosciences Inc. to Report Q4, 2020 Results on Mar 23, 2021

New 90-day low: CA$5.06

Aptose Biosciences Inc. (TSE:APS) Insiders Have Been Selling

Is Aptose Biosciences Inc.'s (TSE:APS) Shareholder Ownership Skewed Towards Insiders?

Independent Director exercised options and sold CA$53k worth of stock

New 90-day high: CA$9.13